Molecular structure of enalaprilatMolecular structure of enalaprilat
Find information on thousands of medical conditions and prescription drugs.

Enalaprilat

Enalapril is an angiotensin converting enzyme (ACE) inhibitor used in the treatment of hypertension and some types of chronic heart failure. Enalapril was the first member of the group of ACE inhibitors known as the dicarboxylate-containing ACE inhibitors. It is marketed by Merck & Co. (Merck, Sharp & Dohme) under the trade names, RenitecĀ® and VasotecĀ®. more...

Home
Diseases
Medicines
A
B
C
D
E
E-Base
Ecstasy (drug)
Edecrin
Edrophonium
Edrophonium chloride
Efavirenz
Effexor
Eflornithine
Elavil
Eldepryl
Elidel
Eligard
Elitek
Elixomin
Elixophyllin
Ellagic acid
Elmiron
Eloxatin
Elspar
Emtriva
Emylcamate
Enalapril
Enalaprilat
Enalaprilat
Endep
Enflurane
Enoxaparin sodium
Entacapone
Enulose
Epi-pen
Epinephrine
Epirubicin
Epitol
Epivir
Epogen
Eprosartan
Ergocalciferol
Ergoloid Mesylates
Ergotamine
Eryc
Eryped
Erythromycin
Esgic
Eskalith
Esmolol
Estazolam
Estazolam
Estrace
Estraderm
Estradiol
Estradiol
Estradiol valerate
Estring
Estrogel
Estrone
Estrostep
Ethacridine
Ethambutol
Ethchlorvynol
Ethosuximide
Ethotoin
Etiracetam
Etodolac
Etopophos
Etoposide
Etorphine
Evista
Exelon
Exemestane
Hexal Australia
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Development

Enalapril was developed by researchers at Merck & Co. as part of their efforts to develop novel treatments for hypertension by modulating the renin-angiotensin-aldosterone (RAS) system.

The success of Squibb in developing the first inhibitor, captopril, provided a major impetus for Merck's research laboratories to develop a competing product. Captopril was not without its problems, however, as it was believed (and shown to be true) that the sulfhydryl-moeity of captoril was responsible for such adverse effects as metallic taste.

Enalaprilat

Enalaprilat, the first dicarboxylate-containing ACE inhibitor, was developed partly to overcome these limitations of captopril. The sulfhydryl-moeity was replaced by a carboxylate-moeity, but additional modifications were required in its structure-based design to achieve a similar potency to captopril.

Enalaprilat itself, however, was not without its problems. The consequence of the structural modifications was that it proved to be have unfavourable ionisation characteristics to allow sufficient potency for oral administration (in tablets). Thus enalaprilat was only suitable for intravenous administration. This was overcome by the researchers at Merck by the esterification of enalaprilat with ethanol to produce enalapril. As a prodrug, enalapril is metabolised in vivo to the active form enalaprilat by various esterases.

A prototype for others

Most importantly, perhaps, the QSAR-based modifications in structure serendipitously led to an improved understanding of the structure of ACE which aided in the development of subsequent carboxylate-containing ACE inhibitors.

Read more at Wikipedia.org


[List your site here Free!]


Neurologic and cardiac progression of glycogenosis type VII over an eight-year period. (Case Reports). : An article from: Southern Medical Journal $5.95 Enalapril plus low-dose eplerenone reduces proteinuria in diabetes; add amlodipine if needed.(Clinical Rounds) : An article from: Family Practice News $5.95

Faulding To Market Enalaprilat Injection/Enalapril Tablets
International pharmaceutical and health care company, F H Faulding & Co Limited (Faulding), Adelaide, South Australia, has announced that its Faulding ...
Focus on...enalaprilat
USE THIS I.V ANTIHYPERTENSIVE DRUG FOR PRE BLOOD PRESSURE CONTROL Mechanism of action: Enalaprilat (Vasotec I.V.) inhibits angiotensin-converting enzyme ...
Report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents
The National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents has issued its Fourth Report on the Diagnosis, Evaluation, and Treatment of High
Resealed erythrocytes: a review: erythrocytes, the most abundant cells in the human body, have potential carrier capabilities for the delivery of drugs.
Erythrocytes, also known as red blood cells, have been extensively studied for their potential carrier capabilities for the delivery of drugs and drug-loaded ...
Professional neglience
ATLA's Professional Negligence Law Reporter includes a broad range of professional liability cases. Here are examples of the kinds of cases appearing in each issue of PNLR CLERGY Sexual abuse of min
Using ACE inhibitors appropriately - Clinical Pharmacology
When first introduced in 1981, angiotensin-converting enzyme (ACE) inhibitors were indicated only for treatment of refractory hypertension. Since then, ...
Act fast during a hypertensive crisis
CARDIOVASCULAR SERIES Initiate treatment immediately to protect your patient from further injury. MAXINE HILL, 59, arrives in the emergency department ...
Faulding Pharmaceuticals Launches Enalaprilat Injection and Enalapril Maleate Tablets
Business/Health Editors ADELAIDE, South Australia--(BUSINESS WIRE)--Aug. 25, 2000 International pharmaceutical and health care company, F H Faulding ...

Home Contact Resources Exchange Links ebay